TrialAlzheimer's research & therapy2023

Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial.

Bruno Dubois et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.